Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas : A literature review with expert opinion
Copyright © 2024 The Authors. Published by Elsevier GmbH.. All rights reserved..
Claudin-18.2 (CLDN18.2) is a member of the tight junction protein family and is a highly selective biomarker with frequent abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer (GC) and esophago-gastric junction adenocarcinomas (EGJA). For these reasons, CLDN18.2 has been investigated as a therapeutic target for GC/EGJA malignancies. Recently, zolbetuximab has been proposed as a new standard of care for patients with CLDN18.2-positive, HER2-negative, locally advanced and metastatic GC/EGJA. The use of CLDN18 IHC assays to select patients who might benefit from anti-CLDN18.2 therapy is currently entering clinical practice. In this setting, pathologists play a central role in therapeutic decision-making. Accurate biomarker assessment is essential to ensure the best therapeutic option for patients. In the present review, we provide a comprehensive overview of available evidence on CLDN18.2 testing and its impact on the therapeutic management of patients with GC/EGJA, as well as some practical suggestions for CLDN18.2 staining interpretation and potential pitfalls in the real-world setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:254 |
|---|---|
| Enthalten in: |
Pathology, research and practice - 254(2024) vom: 09. Feb., Seite 155145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Angerilli, Valentina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.prp.2024.155145 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36768151X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36768151X | ||
| 003 | DE-627 | ||
| 005 | 20240214233154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.prp.2024.155145 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM36768151X | ||
| 035 | |a (NLM)38277741 | ||
| 035 | |a (PII)S0344-0338(24)00056-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Angerilli, Valentina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas |b A literature review with expert opinion |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier GmbH.. All rights reserved. | ||
| 520 | |a Claudin-18.2 (CLDN18.2) is a member of the tight junction protein family and is a highly selective biomarker with frequent abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer (GC) and esophago-gastric junction adenocarcinomas (EGJA). For these reasons, CLDN18.2 has been investigated as a therapeutic target for GC/EGJA malignancies. Recently, zolbetuximab has been proposed as a new standard of care for patients with CLDN18.2-positive, HER2-negative, locally advanced and metastatic GC/EGJA. The use of CLDN18 IHC assays to select patients who might benefit from anti-CLDN18.2 therapy is currently entering clinical practice. In this setting, pathologists play a central role in therapeutic decision-making. Accurate biomarker assessment is essential to ensure the best therapeutic option for patients. In the present review, we provide a comprehensive overview of available evidence on CLDN18.2 testing and its impact on the therapeutic management of patients with GC/EGJA, as well as some practical suggestions for CLDN18.2 staining interpretation and potential pitfalls in the real-world setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Analysis methods | |
| 650 | 4 | |a Claudin 18.2 | |
| 650 | 4 | |a Esophago-gastric junction adenocarcinoma | |
| 650 | 4 | |a Gastric adenocarcinoma | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Therapeutic management | |
| 650 | 7 | |a Cell Adhesion Molecules |2 NLM | |
| 650 | 7 | |a Claudins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a CLDN18 protein, human |2 NLM | |
| 700 | 1 | |a Ghelardi, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Nappo, Floriana |e verfasserin |4 aut | |
| 700 | 1 | |a Grillo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Parente, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Lonardi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Luchini, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrantonio, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Ugolini, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Vanoli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fassan, Matteo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathology, research and practice |d 1980 |g 254(2024) vom: 09. Feb., Seite 155145 |w (DE-627)NLM000326879 |x 1618-0631 |7 nnns |
| 773 | 1 | 8 | |g volume:254 |g year:2024 |g day:09 |g month:02 |g pages:155145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.prp.2024.155145 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 254 |j 2024 |b 09 |c 02 |h 155145 | ||